Research programme: vitamin D3 analogues - Bayer Healthcare Pharmaceuticals
Alternative Names: Vitamin D3 analogues research programme - Bayer Healthcare; ZK 191784; ZK 203278Latest Information Update: 21 Mar 2011
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action Immunosuppressants; Vitamin D3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Immunosuppression
Most Recent Events
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 29 Mar 2010 Preclinical development is ongoing in Germany
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG